FDA advisers warn of more deaths if drug is relaunched.

Ray Moynihan*

*Corresponding author for this work

Research output: Contribution to journalArticleProfessional

5 Citations (Scopus)

Abstract

Advisers to the US Food and Drug Administration are warning of more serious injuries and drug related deaths if alosetron (Lotronex)—a drug for bowel disorders manufactured by GlaxoSmithKline—returns to the market later this year.
Original languageEnglish
Pages (from-to)561-561
Number of pages1
JournalBMJ (Clinical research ed.)
Volume325
Issue number7364
DOIs
Publication statusPublished - 14 Sept 2002

Fingerprint

Dive into the research topics of 'FDA advisers warn of more deaths if drug is relaunched.'. Together they form a unique fingerprint.

Cite this